Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
The said drug is primarily used to treat gastroesophageal reflux disease (GERD), heal acid-related damage to the esophagus.
The aforesaid tentative approval is subject to the expiry of the patent covering the currently listed Reference Listed Drug (RLD), which is expected to occur in December 2026. Final approval is anticipated upon such patent expiry.
The said approval follows successful completion of the pre-approval inspection (PAI) conducted by the United States Food and Drug Administration (USFDA) at the solid dosage manufacturing facility located at Roorkee.
Jubilant Pharmova is an integrated global pharmaceutical company with three business segments, namely pharmaceuticals, contract research and development services, and proprietary novel drugs. The company’s consolidated net profit declined 22.27% to Rs 119.40 crore, while net sales rose 18.60% to Rs 2,272.20 crore in Q4 FY26 compared with Q4 FY25.
The scrip shed 0.84% to settle at Rs 964.05 on Thursday, 25th June 2026. The stock market is shut today on account of Muharram.
Jubilant Pharmova announced that United States Food and Drug Administration (USFDA) has concluded an inspection of Jubilant HollisterStier LLC (JHS)'s contract manufacturing facility located in Spokane, WA. U.S.A on 17 June 2026.
The USFDA had issued eight (8) observations, none of which are related to sterility assurance concerns.
Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is a subsidiary of Jubilant Pharma, Singapore, a wholly owned subsidiary of the company.
Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is a subsidiary of Jubilant Pharma Limited, Singapore, a wholly owned subsidiary of Jubilant Pharmova.
Shares of Jubilant Pharmova shed 0.94% to Rs 965.45 on the BSE.
For the full year,net profit declined 52.53% to Rs 398.50 crore in the year ended March 2026 as against Rs 839.40 crore during the previous year ended March 2025. Sales rose 14.36% to Rs 8225.00 crore in the year ended March 2026 as against Rs 7192.10 crore during the previous year ended March 2025.
KEI Industries Ltd, Jubilant Pharmova Ltd, Poly Medicure Ltd and Shree Renuka Sugars Ltd are among the other losers in the BSE's 'A' group today, 10 March 2026.
Paras Defence and Space Technologies Ltd tumbled 2.73% to Rs 699.45 at 10:53 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 2.1 lakh shares were traded on the counter so far as against the average daily volumes of 4.56 lakh shares in the past one month.
KEI Industries Ltd lost 2.01% to Rs 4694. The stock was the second biggest loser in 'A' group.On the BSE, 9413 shares were traded on the counter so far as against the average daily volumes of 16060 shares in the past one month.
Jubilant Pharmova Ltd crashed 1.97% to Rs 804.7. The stock was the third biggest loser in 'A' group.On the BSE, 6183 shares were traded on the counter so far as against the average daily volumes of 5827 shares in the past one month.
Poly Medicure Ltd dropped 1.91% to Rs 1293. The stock was the fourth biggest loser in 'A' group.On the BSE, 3912 shares were traded on the counter so far as against the average daily volumes of 27469 shares in the past one month.
Shree Renuka Sugars Ltd fell 1.89% to Rs 24.36. The stock was the fifth biggest loser in 'A' group.On the BSE, 1.3 lakh shares were traded on the counter so far as against the average daily volumes of 3.95 lakh shares in the past one month.